Gemcitabine plus capecitabine (Gem–Cape) biweekly in chemorefractory metastatic colorectal cancer

PURPOSE: A proportion of patients with metastatic colorectal cancer (mCRC) are still able to continue with active therapy after their progression to fluoropyrimidines, oxaliplatin, and irinotecan regimens. Studies suggest that gemcitabine and fluoropyrimidines are synergic antimetabolites. The purpo...

Full description

Saved in:
Bibliographic Details
Published in:Clin Transl Oncol
Main Authors: Jiménez-Fonseca, P., Solis, M. P., Garrido, M., Faez, L., Rodriguez, D., Ruiz, A. L., Sanchez Lorenzo, M. L., Uriol, E., Menendez, M. D., Viéitez, J. M.
Format: Artigo
Language:Inglês
Published: Springer Milan 2014
Subjects:
Research Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC4544491/
https://ncbi.nlm.nih.gov/pubmed/25428757
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s12094-014-1243-1
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items